Zydus Cadila has completed Phase 3 Clinical Trial in India of Saroglitazar Magnesium for treating Type 2 Diabetes. The trial was a multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of Saroglitazar compared to Pioglitazone 45mg in patients with Type 2 Diabetes Mellitus. The Phase 3 trial enrolled 1140 subjects and studied the patients over a period of 56 weeks.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Your portfolio may have substantial downside risks!
Review your portfolio with MoneyWorks4me and get it future ready. Let us not miss our hard earned gains. Book your Free demo to discuss with our Experts.